Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland

The 7-valent pneumococcal conjugate vaccine (PCV7) has been shown to be highly cost-effective. The 13-valent pneumococcal conjugate vaccine (PCV13) offers seroprotection against six additional serotypes. A decision-analytic model was constructed to estimate direct medical costs and clinical effectiveness of PCV13 vaccination on invasive pneumococcal disease (IPD), pneumonia, and otitis media relative to PCV7 vaccination. The option with an one-dose catch-up vaccination in children of 15–59 months was also considered. Assuming 83% vaccination coverage and considering indirect effects, 1808 IPD, 5558 pneumonia and 74,136 otitis media cases could be eliminated from the entire population during a 10-year modelling period. The PCV13 vaccination programme would lead to additional costs (+€26.2 Mio), but saved medical costs of −€77.1 Mio due to cases averted and deaths avoided, overcompensate these costs (total cost savings −€50.9 Mio). The national immunisation programmes with PCV13 can be assumed cost saving when compared with the current vaccine PCV7 in Switzerland.

► 13-Valent pneumococcal (PCV13) conjugate vaccine offers additional seroprotection.
► Health benefits and costs associated with vaccination strategies were assessed.
► A decision-analytic model was used to simulate the Swiss birth cohort during 10 years.
► In Switzerland, cost savings were estimated using PCV13 compared to PCV7.